2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 282

From ‘immune Mediated Necrotizing Myopathy’ to ‘antibody-Mediated Necrotizing Myositis: Towards the Pathogenic Role of Anti-SRP and Anti-Hmgcr Antibodies’
Abstract Number: 283

Extracellular Histidyl-tRNA Synthetase in Myositis
Abstract Number: 284

Gene-Environmental Interaction of HLA-DRB1*03:01 and Smoking for the Development of Anti-Jo-1 Autoantibodies in Idiopathic Inflammatory Myopathies: A UK Study
Abstract Number: 285

Antibodies to Small Ubiquitin-like Modifier Activating Enzyme: Frequency and Characteristics of Antibody-Positive Patients in an Unselected Cohort
Abstract Number: 286

Clinical Significance and Prognostic Value of Neutrophil to Lymphocyte Ratio in Patients with Dermatomyositis
Abstract Number: 287

WITHDRAWN
Abstract Number: 288

Glucose Homeostasis Influences the Risk of Incident Knee Osteoarthritis
Abstract Number: 289

Metabolic and Inflammatory Links to Development of Rotator Cuff Tear in Hand Osteoarthritis
Abstract Number: 290

Viscosupplemenation Efficacy in Knee Oa Is Similar in Single-Injection Vs. Multi-Week Formulations and Across OA Severity and BMI Subgroups, but Better in Younger Patients
Abstract Number: 291

Relation of Foot Pronation during Walking to Risk of Worsening Lateral Patellofemoral and Medial Tibiofemoral Cartilage Damage
Abstract Number: 292

Knee Osteoarthritis and the Risk of Fall Injuries Among Older Adults: The Health ABC Study
Abstract Number: 293

A Systematic Review and Network Meta-Analysis of Long-Term Trials of Pharmacological Treatments in Knee Osteoarthritis
Abstract Number: 294

Serum Urate Levels Predict Joint Space Narrowing in Non-Gout Patients with Medial Knee Osteoarthritis
Abstract Number: 295

Efficacy and Safety of Fasinumab for Osteoarthritic Pain in Patients with Moderate to Severe Osteoarthritis of the Knees or Hips
Abstract Number: 296

Knee Osteoarthritis As Risk for Hip Osteoarthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].